Moderna surprise profit lifts shares
Moderna delivers a surprise profit and the announcement of its road map for its experimental RSV vaccine. IGTV's Angeline Ong looks tracks the market reaction.
(AI Video Summary)
Moderna surprises with huge Q4 profits
Moderna, a prominent company in the pharmaceutical industry, pleasantly surprised investors by reporting a profit of $217 million for the fourth quarter. This came as a shock to analysts who were predicting a loss. The company achieved these positive numbers by implementing cost-cutting measures and deferring payments. However, what really thrilled investors was Moderna's future prospects and its plan for an experimental treatment for respiratory syncytial virus (RSV).
Development of new drugs
The announcement about Moderna's RSV treatment caused its stock price to jump up by approximately 6%. Like other pharmaceutical companies, Moderna has been aiming to shift its focus from covid-related products to new pipeline drugs that can fuel growth in the coming years. In 2023, the company's revenue decreased by 44.6%, pushing it to rely on products like cancer drugs, influenza drugs, and vaccines such as the RSV treatment to make up for the decline in covid-related revenue.
Overall, Moderna's unexpected profit and promising outlook have captured the attention of investors, leading to a surge in its stock price. This demonstrates the company's determination to overcome the challenges posed by declining covid-related products by developing new drugs and diversifying its sources of revenue.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
